Black Hawk Acquisition Corp (BKHA) Form 10-Q — Oct 6, 2026
Black Hawk Acquisition's 10-Q for the quarter ended August 31, 2026 shows $12,052 in operating cash, a $2.29 million working capital deficit, and an explicit going-concern warning, though the trust account holds $25.99 million ahead of the October 13, 2026 shareholder vote on its combination with Vesicor Therapeutics. The $70 million pre-money merger with Vesicor Therapeutics is on track: the S-4 was declared effective September 17, 2026, the definitive proxy was filed September 22, 2026, and the deal is expected to close in Q4 2026 with the company renaming itself Vesicor Therapeutics Holdings.
Key figures
- Net Income
- 1303470
- Total Debt
- 1512366
- Total Assets
- 26034667
- Cash Position
- 12052
- Deal Value Usd
- 70000000
- Shares Outstanding
- 4153577
- Q3 eps
- 0.26
- Q3 net income
- 1074736
- Sepa commitment
- 200000000
- Termination date
- 2026-12-22
- Accumulated deficit
- 4713865
- Debt forgiveness gain
- 1015988
- Shareholder vote date
- 2026-10-13
- Trust account balance
- 25993300
- Working capital deficit
- 2294124
- Monthly extension payment
- 150000
- Public shares outstanding
- 2124077
- Forward purchase max shares
- 1350000
- Sponsor convertible notes drawn
- 1515000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.